---
title: "AB&B BIO-TECH-B's Huierkangxin® is the only vaccine selected for the preliminary review list of innovative drugs under the national medical insurance"
description: "AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine HuiErKangXin® has been included in the preliminary review list of innovative drugs for the national medical insurance. T"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252756369.md"
published_at: "2025-08-13T00:23:03.000Z"
---

# AB&B BIO-TECH-B's Huierkangxin® is the only vaccine selected for the preliminary review list of innovative drugs under the national medical insurance

> AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine HuiErKangXin® has been included in the preliminary review list of innovative drugs for the national medical insurance. This vaccine received new drug application approval in May 2023 and is suitable for individuals aged three and above, aiming to provide protection against H1N1, H3N2, and two types of influenza B viruses. The vaccine has undergone significant upgrades based on traditional vaccines, offering advantages such as high purity and low risk of adverse reactions

According to the announcement from the National Healthcare Security Administration on August 12, 2025, Zhonghui Biological-B (02627) announced that the list of innovative drugs for national commercial health insurance that passed the preliminary review this year includes the only vaccine product—the quadrivalent influenza virus subunit vaccine.

The quadrivalent influenza virus subunit vaccine, marketed under the name HuiErKangXin, received approval for its New Drug Application (NDA) from the National Medical Products Administration of China in May 2023. It is intended for use in individuals aged three and older (with a specification of 15μg/0.5ml in terms of the hemagglutinin concentration of the virus strains) and is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025. It aims to provide broad protection against two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages). This product represents a significant upgrade over traditional virus-inactivated vaccines, offering comprehensive protection, high purity of component antigens, and a low risk of adverse reactions

### Related Stocks

- [02627.HK - AB&B BIO-TECH-B](https://longbridge.com/en/quote/02627.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Canada January producer prices up 2.7% on precious metals, lumber | Producer prices in Canada rose by 2.7% in January compared to December, driven by increases in primary non-ferrous metal | [Link](https://longbridge.com/en/news/276446665.md) |
| ConocoPhillips considers selling Permian assets worth $2 billion, Bloomberg News reports | Feb 20 (Reuters) - ConocoPhillipsis exploring a sale of some of its Permian Basin assets as part of a broader streamlini | [Link](https://longbridge.com/en/news/276478732.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Financial Advocates Investment Management Lowers Stock Position in Meta Platforms, Inc. $META | Financial Advocates Investment Management reduced its stake in Meta Platforms, Inc. by 66.7% in Q3, now holding 2,343 sh | [Link](https://longbridge.com/en/news/276432394.md) |
| Rocket Lab Corporation $RKLB Stock Holdings Increased by Vanguard Group Inc. | Vanguard Group Inc. increased its stake in Rocket Lab Corporation (NASDAQ:RKLB) by 5.4% in Q3, owning 41.8 million share | [Link](https://longbridge.com/en/news/276451972.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.